In chronic myeloid leukemia (CML), imatinib may reverse bone marrow fibrosis (MF). Whether the unfavorable prognosis of MF is also reversed and whether imatinib guarantees against evolution of MF are unclear as yet. Fifty-nine patients with Ph þ CML treated with X400 mg imatinib/day were examined for MF in 6-to 12-month intervals. Imatinib effectively reversed initial MF (Po0.0005). However, during a follow-up period of up to 4.8 years, small foci with abnormal fiber increase (FFI) emerged in 8 of 30 pretreated and 6 of 29 non-pretreated patients. Patients with FFI showed a significantly lower probability of achieving a complete cytogenetic or major molecular response (36 versus 81%; Po0.007). During the further follow up, 57% of patients with FFI but none of the other patients suffered from full-blown MF (P ¼ 0.00005). None of the patients with FFI or MF showed a Janus kinase-2 mutation (V617F). Evolutions of FFI and MF were independent significant predictors of imatinib failure (P ¼ 0.0031), accelerated phase and death of patients (P ¼ 0.0001; multivariate analyses). Imatinib effectively reverses initial MF in CML, but neither eliminates its unfavorable prognosis nor guarantees completely against new evolution of MF.
Introduction
Imatinib has significantly improved the therapy of chronic myeloid leukemia (CML). [1] [2] [3] [4] It specifically counteracts the survival advantage of bcr/abl-positive cells, inducing hematologic and cytogenetic remission in the majority of patients. [2] [3] [4] Besides inhibiting bcr/abl-induced increase in tyrosine kinase activity, it also inhibits the platelet-derived growth factor receptor protein kinase a and b 5, 6 and the stimulation of c-Abl kinase activity by transforming growth factor-b, 7 cytokines that are important mediators of fibrogenesis in CML. 8 This inhibition is relevant since marrow fibrosis (MF) is a typical complication of CML [9] [10] [11] [12] that correlates with an unfavorable course of disease. 10, 12, 13 Indeed, reversal of fibrosis was observed in initial studies on imatinib treatment in CML and chronic eosinophilic leukemia with rather small number of patients. [14] [15] [16] [17] [18] [19] However, the two reports on the prognostic significance of initial MF on the outcome during imatinib therapy differ in their results, 20, 21 and representative data on the risk and prognostic relevance of MF emerging during imatinib treatment do not exist as yet. Therefore, we started a pilot study (1) to evaluate whether imatinib reliably prevents evolution of MF in CML, (2) to estimate the possible prognostic significance of MF and its change during imatinib therapy and (3) if MF should emerge or relapse during imatinib therapy, to evaluate whether the evolution of MF can be predicted. Since MF may evolve during long-term therapy with interferon-a (IFN) and chemotherapy (CHT) 10, 22 and since the prognostic significance of MF may be influenced by pretreatment with IFN, 20 ,21 a possible impact of pretreatment with IFN or CHT was taken into consideration.
Patients and methods

Study design
After registration of imatinib as a primary treatment regimen for CML in 2001, 59 patients with Ph þ /bcr-abl þ CML who agreed for imatinib monotherapy and a periodic monitoring of marrow cytogenetics, morphology (bone marrow biopsies; BMBs), molecular response and clinical course of disease were selected to extract morphologic parameters of bone marrow that may provide independent prognostic information during imatinib treatment (histopathologic imatinib trial). In-and exclusion criteria of this trial agreed with those from the German CML Study IV 23 except for one point: pretreatment with CHT or IFN-a was not an exclusion criterion. The study was conducted in accordance with the Declaration of Helsinki and the regulations of the Central Ethics Committee of Hannover Medical School, and the data of the patients were anonymized completely.
The imatinib dose was 400 mg day À1 with an increase of up to 800 mg in the case of no partial hematologic remission 3 months after the start of the therapy or no major cytogenetic response (that is, X35% Ph þ metaphases) after 6 months. In 12 patients, the imatinib dose was increased to 600 or 800 mg day À1 and in two patients, low-dose cytosine arabinoside was added to improve effectiveness of treatment. In one case, the dose was reduced to 300 mg day À1 due to side effects of therapy. The 30 patients recruited first had been pretreated with CHT or IFN-a (for details see Table 1 ). Therapy was changed to imatinib as second-line treatment because of low efficacy or side effects of the pretreatment regimen. In other patients, treatment with imatinib monotherapy was started within 2 weeks after diagnosis of disease, in five of them after a short initial induction with hydroxyurea (4 weeks). Since the prognostic effects of risk scores 24, 25 were not markedly altered by pretreatment, multivariate analyses were not split according to pretreatment of patients, but pretreatment was included as an independent variable in the statistical models.
Among the pretreated patients, six showed progressive CML (first accelerated phase according to the criteria of the World Health Organization 26 ) during the pretreatment period, one of them with 19% blasts in the peripheral blood at the start of imatinib treatment. The other pretreated patients were in first chronic phase on the day when imatinib therapy was started.
The findings from 30 further patients with healthy bone marrow served as an age-matched control for normal fiber content, and the data of these patients were also anonymized.
Monitoring of patients
The histomorphometric results were correlated with clinical, hematologic, cytogenetic and molecular genetic data before and during therapy on the days when the BMBs were taken; at 3-to 6-month intervals during the first year of imatinib treatment and at 6-to 12-month intervals thereafter.
Hematologic, cytogenetic and molecular response. Hematologic and cytogenetic remission was defined as described by an international expert group. 27 Cytogenetic data on the basis of at least 20 metaphases evaluated on a day when a biopsy had been taken were available from 55 patients before the start of the imatinib treatment and from all 59 during therapy. Three patients showed a variant Philadelphia translocation. One patient who was Philadelphia-chromosome-negative and bcr/ abl-positive was not considered when evaluating the cytogenetic response.
Among imatinib-treated patients with a complete cytogenetic remission and the one who was Philadelphia-chromosomenegative and bcr/abl-positive, a major molecular response was defined using real-time PCR (RT-PCR) in peripheral blood samples (20 ml) as a bcr-abl/G6PD ratioo0.025%, which is equivalent to a 3 log reduction of a baseline level of 25%, that had been defined as the median level of bcr-abl/G6PD transcripts in the blood of 44 patients with untreated CML in chronic phase 2 (mean7s.d.: 29716%; range: 1-86%).
JAK-2 mutation. From all patients with emergence or relapse of foci with increased fiber deposition (FFI) or MF, the last biopsy with FFI or MF was evaluated for cells with V617F mutation in the JH2 pseudokinase domain of the Janus kinase-2 (JAK-2). DNA was extracted from all marrow cells within a 10 mm slide taken from the biopsy. DNA extraction, JAK-2 amplification, BsaXI restriction site analysis, JAK-2 (V617F) genotyping and allele quantification by pyrosequencing were performed as described earlier.
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End points. Accelerated phase during imatinib treatment, imatinib failure and suboptimal response were defined according to the recommendations of an international expert panel. 27 The end point of the 'acceleration-free survival' was set when acceleration or death of the patient occurred. The median period of follow-up was 33 months (mean: 40 months; 25th to 75th percentiles: 17-58 months), starting the analyses from the first day of imatinib treatment. The follow-up evaluations of six patients who received stem cell allografts were censored at the time of transplantation.
Evaluation of marrow fibrosis
A total of 179 BMBs from patients with CML or normal marrow were examined for MF ( Table 1 ). The BMBs were 17 Â 2 Â 2 mm 3 in mean size. MF was evaluated by blinding the examiner to patients' data and using an exact approach quantifying the volume ratio V MF of marrow affected by fibrosis. 9, 10 The results from this method correlate with a semiquantitative grading of MF. 9 According to our observations, this method appears to be superior to all other currently known approaches to prove and quantify MF considering sensitivity, specificity, precision, reproducibility, prognostic relevance of results 9 and adjustability to influences from technical processing of BMBs. 29 A ratio V MF o0.05 is equivalent to the fiber content in normal healthy marrow. A ratio between 0.05 and 0.15 indicates FFI, and a ratio V MF 40.15 corresponds to MF in semiquantitative grading. 9 Sections of 3 mm in thickness were cut. The collagen and reticulin fibers were marked by applying Gomori silver impregnation. Marrow areas free from bone and artifacts were investigated, measuring 1275 mm 2 with an average of 0.870.3 Â 10 5 marrow cells. The time consumption was B20 min per slide. The reproducibility of the results from this method was confirmed when 241 BMBs randomly selected from another CML study and mixed with the BMBs of the imatinib trial were additionally evaluated with blinding to patients' data and the previous measurements from another examiner: V MF 7s.d.: 0.08670.156 versus 0.08570.159; correlation coefficient between both measurements: r ¼ 0.976.
Statistical analyses
After recruitment of more than 50 patients (59 patients), an initial analysis was started with respect to reversal, emergence and prognostic significance of MF. The effect of therapy on the development of V MF was tested applying the mixed effect regression model. 30 Graphical presentation of the risk of MF not reversing during imatinib treatment was adjusted to the time intervals between sequence BMBs by programming polygons on the basis of the measured V MF on the days when the BMBs were taken and estimating the time intervals until V MF ¼ 0.15 on the basis of these polygons. The log-rank test and the Cox model were used to test the significance of variables with respect to the following events: complete reversal of FFI and MF, emergence or relapse of FFI and MF, clonal evolution of disease, detection of imatinib failure and occurrence of acceleration during imatinib treatment or death of patients (acceleration-free survival). Probabilities of Po0.05 (two-tailed testing) were regarded as 'significant'. When included as an independent variable in the statistical models, the molecular response was considered according to the lowest level of the bcr-abl transcripts (maximum response) observed during therapy. All other variables that changed during therapy were included as time-dependent covariates by programming polygons on the basis of the findings on the days when the BMBs were taken.
Results
Fiber content before the start of imatinib therapy, comparison with normal bone marrow Before the start of the imatinib trial, marrow fiber content V MF exceeded that from normal marrow by a factor of 410 with V MF 40.05 (FFI or MF) in 30.5% (n ¼ 18, Figure 1a) Figure 1a ; for details see Supplementary Figure 1) . Among a total of 14 patients who suffered from full-blown MF either before or during imatinib treatment, MF reversed in 8 (57.1%). The probability of a remission of FFI and MF was not influenced significantly by pretreatment with IFN or CHT (P40.1; for details see Supplementary Figure 1a) . In multiple regression analysis, the application of X400 mg imatinib/day and its duration were the most important influences on decrease of V MF (Po0.0005), independent of the other important independent influence, the fiber content before the start of imatinib treatment (Po0.0005). The median period of time until normalization of V MF o0.05 was 6-12 months (for details see Supplementary Figure 1 ).
Relation to the degree of hematologic, cytogenetic and molecular response. An initial increase of V MF normalized independently of the degree of hematologic, cytogenetic and major molecular response achieved during imatinib therapy (P40.1; for details see Supplementary Figure 1b) .
Emergence of FFI and MF
During imatinib therapy, FFI (Figure 1b ) emerged in 14 patients (Figure 1a) , in six without any pretreatment and in eight after a pretreatment with IFN or CHT. Full-blown MF (Figure 1d ) emerged in eight patients. In two of them, MF reversed after increase of imatinib dose, and in six, it did not reverse ( Figures  1a and c) . The probability that FFI and MF had emerged 'by chance' was low (Po0.0005). V MF (FFI, MF) progressed independently of pretreatment with IFN or CHT (P40.1).
FFI and progress to full-blown MF. Among patients with no FFI before or during therapy, emergence of full-blown MF was not observed, whereas all the patients with MF before or during the first 3 months of imatinib treatment (n ¼ 6) showed small FFI beside the marrow regions with fibrosis, and all the patients who suffered from MF during imatinib therapy (n ¼ 8) had shown FFI 6-12 months earlier (Figure 1d ; P ¼ 0.00005). In multiple regression analysis, FFI were the most important independent predictor of progressive increase of V MF during therapy (P ¼ 0.008) independent of the fiber content before start of treatment and the duration of disease, and all the other variables (including the risk scores) lost their predictive significance with respect to the occurrence of MF when FFI were taken into consideration.
Dependence on the degree of hematologic, cytogenetic and molecular response. FFI and MF emerged independently of a hematologic remission (P40.1). Full-blown MF was not observed during a complete cytogenetic or a major molecular response. However, a complete cytogenetic and a major molecular response did not guarantee against new emergence of small FFI, which were observed in the marrow from five patients; in three of them without and in two with a major molecular response. FFI distinguished CML from normal marrow even in the case of a complete hematologic, cytogenetic or major molecular remission (Po0.00005). However, when bcr/abl transcripts became undetectable (n ¼ 9), FFI and MF were not observed.
Contribution of FFI and MF to progress of disease Clonal evolution of disease. Clones with additional numeric or structural aberrations besides t(9;22)(q34;q11) were observed in 9.1% of patients before the start of the trial (Table 1) , and clonal evolution with secondary numeric or structural aberrations besides t(9;22)(q34;q11) occurred in 13.6% of patients after the start of the treatment (8/59). MF was not an independent predictor of clonal evolution of disease, and MF evolved independently of occurrence of secondary karyotype abnormalities (P40.1). Among a total of eight patients with clonal evolution, MF emerged in 2 (25%): (1) of two patients with evolution of complex karyotype abnormalities, MF emerged in one, and (2) among six patients with evolution of a single secondary numeric or structural chromosome aberration besides t(9;22), MF emerged in one with an additional translocation t(1;18). Furthermore, in all patients with new emergence of FFI or MF during imatinib treatment (n ¼ 14), the JAK-2 mutation status (V617F) was evaluated in their last biopsy with FFI or MF, and a V617F mutation was not detected.
Suboptimal response, imatinib failure. A pathologic increase of V MF (FFI or MF) before start or within the first 3 months of imatinib therapy did not reduce the probability of achieving a complete hematologic response during imatinib treatment, which was achieved in 95% of patients (18/19; P40.1). However, a complete cytogenetic remission and/or a major molecular response were observed significantly less often than in patients with an initial normal fiber content (6/19 ¼ 32% versus 26/40 ¼ 65% during the first year of imatinib treatment; P ¼ 0.01; Figure 2a ), and none of the patients with full-blown MF before or during the first 3 months of imatinib treatment (n ¼ 6) achieved a major molecular response throughout therapy.
In patients with new emergence of FFI or MF during imatinib treatment, the probability of achieving a complete hematologic response was not significantly reduced (P40.1). However, these patients showed a significantly lower probability of achieving a complete cytogenetic or a major molecular response (5/14 ¼ 36 versus 21/26 ¼ 81% during the first year of imatinib treatment; Po0.007).
In multivariate analysis, FFI that had occurred before the start of imatinib therapy did not provide unfavorable prognostic information on failure of imatinib treatment when they completely reversed and did not relapse during imatinib treatment (Table 2) . However, the majority of patients with emerging or relapsing FFI suffered from imatinib failure, and the predictive significance of the change of V MF during treatment on the risk of imatinib failure was independent of the impact of all the other variables taken into consideration (P ¼ 0.0031; Table 2 ).
Acceleration-free survival. During the follow-up period of 4.8 years, five patients died, all after new emergence, persistence or relapse of FFI, with occurrence of full-blown MF in four of them. Among the survivors (n ¼ 54), 63% of Marrow fibrosis during imatinib therapy of CML G Buesche et al patients with full-blown MF (5/8) suffered from acceleration or blast crisis during the further period of follow up, a value that was significantly higher than that observed in the other patients (5/46, 10.9%; Po0.005; Figure 2b . As proposed by an international expert panel, 27 MF was not included in the definition of accelerated phase). In contrast to FFI, the unfavorable prognostic effect of full-blown MF was independent of whether it had occurred before or during imatinib treatment and whether or not it had (temporarily) reversed (Figure 2c) . In multivariate survival analysis (acceleration-free survival), the prognostic significance of V MF was independent of the impact of all the other variables taken into consideration (P ¼ 0.0001; Table 2 ).
Pretreatment with IFN or CHT. During the period of observation, pretreatment with IFN or CHT did not provide independent prognostic significance (imatinib failure, acceleration-free survival; Table 2 ; P40.1).
Discussion
Our observations confirm a complete reversal of a pathologic fiber increase in B70% of patients during the first 2 years of imatinib therapy of CML; in 50% of them, V MF normalized within the first year of treatment. MF reversed independently of a cytogenetic and molecular remission of disease, which gives evidence for a direct antifibrotic effect of imatinib, probably due to its inhibition of the platelet-derived growth factor receptor protein kinase a and b. 5, 6 The antifibrotic efficacy of imatinib does not furthermore appear to be influenced by failure of a previous therapy with IFN and CHT, which may indicate a superior antifibrotic efficacy of imatinib. Nevertheless, a direct comparison with the antifibrotic effect of a combination therapy with high-dose IFN-a and low-dose cytosine arabinoside 22 does not exist as yet.
In contrast to the rather fast reversal of initial MF, imatinib does not absolutely guarantee against evolution of MF, an observation restricted not only to patients pretreated with IFN or CHT; emergence of FFI or MF was also observed in patients not pretreated by another therapy regimen. The difference with previous reports not having observed progressive full-blown fibrosis during imatinib treatment, 14 or describing it as a rare event, [15] [16] [17] can be put down to a lower sensitivity of the approaches used to prove and quantify MF, 9 shorter periods of follow-up 14 or smaller sample sizes. [14] [15] [16] [17] Nevertheless, although the number of patients with full-blown MF reported in these publications are rather small, [15] [16] [17] it should be mentioned that the reported frequencies of MF in 2/13, 3/20 and 1/40 patients in chronic phase within follow-up periods of 2 years agree well with our observation of the risk of emergence of full-stage MF.
The mechanisms of failure of imatinib therapy are manifold, 31 including loss of the inhibitory effect of imatinib on bcr-abl 32, 33 or on stimulation of c-Abl kinase activity by transforming growth factor-b, 7 inactivation of tumor suppressor p53, 34 or alteration of the expression of genes involved in DNA repair, apoptosis, cell adhesion or drug metabolism. 35, 36 Expansion of a JAK-2-mutated clone (V617F) as a possible mechanism of emerging MF during imatinib therapy of CML has recently been reported. 37 However, a JAK-2 V617F mutation is uncommon in CML 38 and none of the patients from our study who suffered from FFI or MF showed a JAK-2 mutation (V617F) in their bone marrow cells. A loss of the inhibitory effect on platelet-derived growth factor receptor protein kinase activity 5, 6 might explain the emergence of foci with fiber increase during a cytogenetic and molecular response. However, representative data on the molecular mechanism of evolving or progressing fibrosis during imatinib treatment of CML do not exist as yet.
Additional chromosome aberrations besides t(9;22)(q34;q11) indicate clonal evolution of disease [39] [40] [41] and are usually regarded as an indicator of loss of efficacy of treatment. 31, 33, 39, 40 Apart from a few patients with complex karyotype abnormal- Figure 2 Relevance of FFI and full-blown MF to the probability of a cytogenetic or molecular response and the risk of acceleration or death of patients. Among the patients with FFI or MF before or within the first 3 months after the start of imatinib treatment, the probability of achieving a complete cytogenetic or major molecular response was markedly reduced compared to the patients with an initial normal fiber content ((a) complete cytogenetics of major molecular response after detection of FFI or MF before the start of imatinib treatment). Among patients with FFI, the acceleration-free survival time was significantly reduced only when a transformation to full-blown MF had occurred ((b) acceleration-free survival dependent on occurrence of MF before or during imatinib therapy; Po0.000005) and the unfavorable prognosis of full-blown MF was independent of whether or not having reversed during treatment ((c) acceleration-free survival dependent on whether or not MF had reversed during imatinib therapy; P40.1; Kaplan-Meier analyses).
ities, the evolution of secondary chromosomal aberrations was not a reliable predictor of oncoming MF, and the unfavorable prognostic effect of MF was independent of the evidence of additional chromosome aberrations. Nevertheless, the periods of observation during imatinib treatment still appear to be too short for a final conclusion.
An earlier report on a reduced probability of achieving a cytogenetic response in patients with MF 20 is confirmed by our observations. However, this relation was also true for patients without obvious fibrosis, but with small FFI in their bone marrow, an observation not reported as yet. MF evolved out of such FFI, which, therefore, were the most important predictor of full-blown MF during imatinib therapy, a novel observation supporting the usefulness of the volumetric approach applied to detect and quantify fibrosis and its precursor in bone marrow. 9 The focal evolution of fibrosis within the bone marrow indicates that fibrosis induction appears to be an acquired feature during a clonal evolution of CML rather than a characteristic from the beginning of disease, particularly as a direct fibrosis induction by the BCR-abl fusion protein has not been shown as yet.
The relevance of FFI and its adequate registration is underlined by the observation that they may evolve not only after therapy failure, but also during a complete cytogenetic or a major molecular response. Since the ability of a CML clone to induce MF is not a consequence of its quantity, but of its ability to produce other growth factors, particularly platelet-derived growth factor-a/-b or transforming growth factor-b, 8 this finding should not be a surprise. Even in the case of a major molecular response, a focus with 40-90 bcr-abl-positive cells may be expected within the 10 5 marrow cells of a marrow biopsy section, which may be enough to induce a focus with fiber increase. Similar to the loss of differentiation (blast crisis), oncoming MF indicates a qualitative change of disease indicating the evolution of a (more malignant) clone resistant to the (antifibrotic) effect of imatinib treatment and thus, predicting progress of the disease.
Similar to the observations during imatinib treatment of a myeloproliferative variant of the hypereosinophilic syndrome, 18 evolution of MF may be reliably prevented only by a marked reduction of tumor mass resulting in undetectable bcr/abl transcripts (RT-PCR). Since imatinib may induce bcr/abl negativity in more than 10% of patients, 42 it may prevent evolution of MF in a significant proportion of patients. However, it is likely that imatinib does not completely eliminate the neoplastic clone 33, 43 so that the question of a long-term antifibrotic effect of imatinib treatment cannot be regarded as answered as yet.
On the basis of these findings, it should not be a surprise that, although an inverse correlation between the cytogenetic and molecular response and the extent of MF could be detected, the prognostic relevance of MF was not explained by this correlation. Monitoring of the marrow volume V MF with an abnormal fiber increase provided significant independent prognostic information on the outcome during imatinib therapy of CML, particularly the acceleration-free survival of patients and an early detection of imatinib failure. These data support previous observations during therapy with IFN or CHT. 10, 22 First data from the pilot phase of the German CML Study IV show similar results. 44 Thus, although imatinib therapy reverses initial MF, it does not appear to reverse its unfavorable prognosis. Therefore, we conclude that MF still appears to be an important poor prognostic factor in CML, not only in its late, advanced stage, 20 but also at its beginning, that is when it emerges or relapses.
MF evolves focally within bone marrow, and it becomes diffuse when not reversing during therapy. FFI appear to be a morphologic equivalent of a clonal evolution of CML when occurring during imatinib treatment, indicating the expansion of Without consideration of V MF , the cytogenetic and molecular response achieved during imatinib treatment was most significant. However, after consideration of V MF , all the other variables lost their significance; their prognostic information was not independent of that of V MF . Initial of V MF did not provide independent prognostic information with respect to the detection of an imatinib failure, but with respect to the acceleration-free survival. Since the Sokal Index was not superior to the Hasford Score (univariate analyses), the Sokal Index was not included in the multivariate analyses.
Relative risk, change in the hazard rate for one unit increase of V MF . n.s., not significant. a 'À' no major molecular response, '+' o35% Ph + metaphases, '++' complete cytogenetic response, '+++' major molecular remission, '++++' bcr/ abl-transcripts undetectable. Achieved during the period of pretreatment.
Marrow fibrosis during imatinib therapy of CML G Buesche et al a clone resistant to the antifibrotic efficacy of this tyrosine kinase inhibitor.
In CML, MF should be diagnosed and quantified on the basis of an exact approach that allows precursor lesions of MF to be diagnosed. The unfavorable prognostic relevance of MF and its precursors may be underestimated if applying a semiquantitative grading, 21 which ignores FFI and misclassifies patients as having an MF or not in a significant proportion of cases. 9 Imatinib treatment should not be continued at the current dose in the case of increasing V MF and emerging FFI during therapyFregardless of the degree of hematologic, cytogenetic and molecular response, and a monotherapy with 400 mg imatinib per day does not seem to eliminate the unfavorable prognosis of full-blown MFFeven when completely reversing during therapy. Other treatment concepts should therefore be taken into consideration to improve the survival time of these patients.
Considering the similarities in the results observed during treatment with IFN and CHT, 10, 22 imatinib does not seem to change the 'biology' of CML fundamentally although it acts in a significantly more specific and effective way; a progression can also be detected in patients treated with this tyrosine kinase inhibitor. Since evolution of MF is a typical complication during the course of CML, 9 it is recommended (a) not to forget MF when considering suboptimal response, imatinib failure and accelerated phase, (b) to check the bone marrow for this complication in a regular scheme (6-to 12-month intervals) and (c) to test its prognostic relevance in prospective controlled trials on imatinib treatment.
